AbCellera Biologics (ABCL) Change in Cash (2020 - 2026)

AbCellera Biologics has reported Change in Cash for 7 years, with the latest figure at -$51.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 1849.4% year-over-year to -$51.4 million; the trailing twelve-month figure through Mar 2026 stood at -$82.8 million (down 331.85% YoY), and the FY2025 full-year result was -$28.4 million, down 223.3% from the prior year.
• Change in Cash for Q1 2026 stood at -$51.4 million, down from $44.8 million in the prior quarter.
• The five-year high for Change in Cash was $245.8 million in Q2 2022, with the low at -$417.4 million in Q3 2022.
• Historically, Change in Cash has averaged -$23.4 million across 5 years, with a median of -$9.3 million in 2025.
• Annual changes were most pronounced in 2024 — Change in Cash surged 286.42% — and 2026, when it plunged 1849.4%.
• AbCellera Biologics' Change in Cash stood at $14.6 million in 2022, then tumbled by 368.51% to -$39.1 million in 2023, then surged by 175.92% to $29.7 million in 2024, then soared by 50.92% to $44.8 million in 2025, then tumbled by 214.84% to -$51.4 million in 2026.
• The last three Change in Cash figures came in at -$51.4 million (Q1 2026), $44.8 million (Q4 2025), and -$9.3 million (Q3 2025), per Business Quant data.